Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$74.51 USD

74.51
1,138,656

-0.27 (-0.36%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $74.49 -0.02 (-0.03%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 248)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Baxter's (BAX) New Launch to Support Complex Critical Care Needs

Baxter's (BAX) Progressa+ bed for the ICU is expected to enhance workflow and reduce strain on nursing resources.

PacBio (PACB) Gets New Order for Revio System From Bioscientia

PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disorders.

Thermo Fisher's (TMO) New Launch to Advance Cancer Therapies

Thermo Fisher's (TMO) Gibco OncoPro Tumoroid Culture Medium Kit is intended to increase researchers' access to sophisticated cancer models.

OPKO Health's (OPK) NGENLA Approved by FDA for GHD Treatment

The latest approval for OPKO Health's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.

Walgreens (WBA) to Advance Diabetes Care at FFL Conference

Walgreens (WBA) will sponsor Children with Diabetes' FFL event to make a difference in the lives of the 122 million individuals afflicted by diabetes and pre-diabetes.

Hologic (HOLX) Dips More Than Broader Markets: What You Should Know

Hologic (HOLX) closed the most recent trading day at $80.24, moving -0.72% from the previous trading session.

Three Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

Investors are optimistic about Myriad Genetics (MYGN) due to the performance of its oncology business and product launches.

Amedisys (AMED) to Advance Value-Based Care With Optum Merger

Amedisys' (AMED) combination with Optum brings together two organizations committed to offering patients and their families compassionate, value-based comprehensive care.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health (CVS) backed by the acquisition of Oak Street Health, which broadens its value-based primary care platform.

Here's Why You Should Invest in DENTSPLY SIRONA (XRAY) Stock

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

McKesson's (MCK) Latest Launch to Give Access to OTC Products

McKesson's (MCK) latest launch is expected to meet the evolving needs and growing demand for quality OTC private-label health and wellness products.

Three Reasons to Add Masimo (MASI) Stock to Your Portfolio

Masimo's (MASI) solid product suite raises optimism about the stock.

Dexcom (DXCM) to Launch New Product in 2024, Ups Long-Term View

Dexcom (DXCM) announces encouraging developments in 2024, including faster coverage for its products by private payers and new product launch for diabetic patients not on insulin.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

Investors are optimistic about Abbott (ABT) on continued growth in Diabetes business and upbeat guidance.

Inspire Medical (INSP) Hits 52-Week High: What's Aiding It?

Investors are optimistic about Inspire Medical's (INSP) global presence.

Masimo's (MASI) W1 to Boost Virtual Care in Preoperative Patients

Masimo's (MASI) W1 advanced health-tracking watch is expected to provide better insights into pre-operative patients' heart rate variability data and improve pre-habilitation.

Envista (NVST) Gains From New Acquisitions Amid FX Woes

Envista's (NVST) implant businesses in Europe perform well on the back of disciplined commercial execution.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein (HSIC) due to the performance of its dental business.

Abbott (ABT) FreeStyle Libre 2 Gets Reimbursement in France

Abbott's (ABT) FreeStyle Libre increased reimbursement makes it possible for more people in France with diabetes to use the recent CGM technology.

Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its product innovation aiding growth.

Boston Scientific's (BSX) New Launches Aid Amid Cost Pressure

Boston Scientific (BSX) remains excited about the rest of 2023 and expects to continue to outpace its peers within the EMEA market.

Hologic (HOLX) Gains But Lags Market: What You Should Know

Hologic (HOLX) closed at $81.49 in the latest trading session, marking a +0.07% move from the prior day.

Quest Diagnostics' (DGX) New Buyout Expands Cancer Portfolio

Quest Diagnostics (DGX) will use MRD technology to create new blood-based clinical lab services for solid tumour cancers that will be available starting in 2024.

Masimo's (MASI) Launch to Serve the Personalized Hearables Market

Masimo's (MASI) new product offerings are expected to enable it to expand its footprint in the personalized hearables market.